MyoKardia, Inc. is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. 

About Cardiomyopathies

Heartbeats: A Conversation with The Hypertrophic Cardiomyopathy Experts

News & Events

December 2, 2016
MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491
Link

December 1, 2016
MyoKardia Announces Appointment of Marc Semigran, M.D., as Chief Medical Officer
Link

November 11, 2016
MyoKardia Announces Exploratory Digital Health Substudy as Part of PIONEER-HCM Trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
Link

November 7, 2016
MyoKardia Reports Progress on Clinical Programs and Third Quarter 2016 Financial Results
Link

November 4, 2016
MyoKardia Announces Presentations at American Heart Association Scientific Sessions 2016
Link